...
首页> 外文期刊>Journal of drugs in dermatology: JDD >Efficacy of Isotretinoin and Acitretin in Treatment of Frontal Fibrosing Alopecia: Retrospective Analysis of 54 Cases
【24h】

Efficacy of Isotretinoin and Acitretin in Treatment of Frontal Fibrosing Alopecia: Retrospective Analysis of 54 Cases

机译:异黄素和丙酸素治疗前纤维症的疗效治疗54例的回顾性分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

This study aimed to assess the efficacy of systemic retinoids in treating frontal fibrosing alopecia (FFA). It was based on a retrospective analysis of 54 female patients with FFA treated with: oral isotretinoin at the daily dose of 20 mg (29/54) or acitretin at the daily dose of 20 mg (11/54) or with oral finasteride 5 mg/daily (14/54). The study was conducted between 2007 and 2017 The basic of the study is the measurement of distance between the frontal hairline and the glabellar crease prior to the commencement of treatment and after 6, 12, and 24 months. The treatment with systemic retinoids lasted between 12 and 16 months (the mean duration of treatment was 13.5 months). The primary treatment goal was defined as no further progression of disease after 12 months of treatment, while the secondary treatment goal was defined as no further progression of disease following the discontinuation of systemic retinoids. The primary treatment goal was achieved by 76% (23/29) of patients treated with isotretinoin, 73% (8/11) of patients treated with acitretin, and 43% (6/14) of patients treated with finasteride. The secondary treatment goal was achieved by 72% (21/29) of patients treated with isotretinoin, 73% (8/11) of patients treated with acitretin, and 43% (6/14) of patients treated with finasteride. Thus, the administration of systemic retinoids may be beneficial for the stabilization of frontal hairline in patients with FFA.
机译:本研究旨在评估系统性维甲酸治疗额叶纤维性脱发(FFA)的疗效。该研究基于对54名女性FFA患者的回顾性分析:口服异维甲酸20毫克(29/54),阿维a 20毫克(11/54),或口服非那雄胺5毫克/天(14/54)。这项研究是在2007年至2017年期间进行的。该研究的基础是在开始治疗前以及治疗6、12和24个月后测量额叶发际线和眉间皱褶之间的距离。系统性维甲酸治疗持续12至16个月(平均治疗时间为13.5个月)。主要治疗目标被定义为在治疗12个月后没有进一步的疾病进展,而次要治疗目标被定义为在停用系统性维甲酸后没有进一步的疾病进展。76%(23/29)的异维甲酸患者、73%(8/11)的阿维A酸患者和43%(6/14)的非那雄胺患者实现了主要治疗目标。72%(21/29)的异维A酸患者、73%(8/11)的阿维A酸患者和43%(6/14)的非那雄胺患者实现了二级治疗目标。因此,给予系统性维甲酸可能有利于FFA患者额叶发际线的稳定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号